Antibodies
5 September 2013
Takeda’s New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis4 September 2013
XBiotech Announces it is Developing Therapy for MRSA3 September 2013
Baxter and Coherus Biosciences Announce Collaboration to Develop and Commercialize Biosimilars3 September 2013
Simultaneous Applications Submitted to FDA and EMA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder3 September 2013
Novartis receives EU approval for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis2 September 2013
WILEX subsidiary Heidelberg Pharma signs license agreement for the development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche2 September 2013
Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients2 September 2013
Roche’s new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer28 August 2013
EPIRUS Biopharmaceuticals Announces Positive Phase 3 Data Supporting Biosimilarity of BOW-015 to Remicade27 August 2013
Roche’s lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration20 August 2013
Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)19 August 2013
Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises15 August 2013
Dyax Corp. Announces Dosing of First Subject in Phase 1 Trial of DX-2930 for Prevention of HAE Attacks13 August 2013
Lilly Announces Phase III Necitumumab Study Meets Primary Endpoint of Overall Survival13 August 2013
XstalBio Launches CentuRecon™ to Accelerate the Delivery of Biologic Drugs at High Concentration12 August 2013
Immunomedics Advances Solid Tumor Antibody-Drug Conjugate Programs to Phase II Clinical Trials12 August 2013
Biocon Launches ALZUMAb- a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India8 August 2013
GSK to discontinue manufacture and sale of the BEXXAR® therapeutic regimen (tositumomab and iodine I 131 tositumomab)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports